- All major U.S. stock indexes down >1%
- Comm svcs weakest of S&P sectors; tranports off ~2%
- Powell: time to retire word "transitory"
- STOXX off ~0.6%
- Dollar up; gold, bitcoin dip; crude drops
Nov 30 (Reuters) - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at email@example.com
TUESDAY DATA: HAVE YOURSELF AN OMICRON CHRISTMAS (1110 ET/1610 GMT)
Data released on Tuesday revealed a few clouds in the sky with respect to consumer attitudes and factory activity, even as home prices zoom further into the stratosphere. To add insult to injury, the emergence of the Omicron COVID-19 variant suggests the pandemic is not inclined to give up the ghost just yet.
Register now for FREE unlimited access to Reuters.com
With the holiday shopping season in full swing, the mood of the consumer, who does the economic heavy lifting by contributing about 70% of U.S. GDP, continued to dim this month. read more
The Conference Board's (CB) consumer confidence index (USCONC=ECI) slid by 2.1 points in November to 109.5, undershooting economist forecasts.
"Expectations about short-term growth prospects ticked up, but job and income prospects ticked down," writes Lynn Franco, CB's senior director of economic indicators. "Concerns about rising prices—and, to a lesser degree, the Delta variant—were the primary drivers of the slight decline in confidence."
But what about Omicron?
While Lynn expects "a good season for retailers," she adds that "confidence and spending will likely face headwinds from rising prices and a potential resurgence of COVID-19 in the coming months."
Delving into the report's subcomponents, survey respondents grew slightly more pessimistic about both their current situation and near-term expectations both slipped.
But the gap between those two measures remains unusually wide.
If past is prologue, that exaggerated gap could be a harbinger of impending recession, as shown in the graphic below:
Growth of U.S. home prices eased up a bit in September but are still running white-hot.
The S&P Case Shiller's 20 city composite (USSHPQ=ECI) shaved 0.5 percentage points to a year-on-year print of 19.1% coming in a shade below the 19.3% consensus.
The demand wave has been supported by a pandemic that seems to keep finding new ways to linger, and combined with still-low inventories and scarce building supplies, home prices show few signs of coming back to earth.
"Housing prices continued to show remarkable strength in September, though the pace of price increases declined slightly," writes Craig Lazzara, managing director at S&P DJI.
But is this a wave, or the new normal?
"More data will be required to understand whether this demand surge represents simply an acceleration of purchases that would have occurred over the next several years, or reflects a secular change in locational preferences," Lazzara adds.
Every city in the 20-city composite posted double-digit annual gains, with Phoenix in the lead for the 28th consecutive months, with 'valley of the sun' home prices up an astounding 33.1% over 12 months ago.
Finally, activity and midwest factories has cooled this month.
Chicago purchasing managers' index (PMI) (USCPMI=ECI) slid by a steeper-than-expected 6.6 points to reading of 61.8, according to MNI Indicators.
A PMI number over 50 signifies expanded activity over the previous month.
While the Omicron variant outbreak is too recent to have affected the data, the stubborn longevity of health crisis and the effects its having on the global supply chain is likely to remain a drag on the manufacturing sector.
As Rubeela Farooqi, chief U.S. economist at High Frequency Economic observes, "potential moderation in momentum over coming months, if supply bottlenecks and shortages intensify in response to renewed Covid restrictions."
The graphic below compares Chicago PMI with the closely-watched, national PMI figure from the Institute for Supply Management, which is due to deliver its November figure on Wednesday. Analyst see that number inching up to an even 61 from October's 60.8.
Wall Street is taking the gathering Omicron storm to heart, with all three major U.S. stock indexes deep in red territory.
JPMORGAN LOOKS OVERSEAS FOR EQUITY OUTPERFORMANCE NEXT YEAR 1000 ET/1500 GMT)
JPMorgan says emerging markets and European stock markets are likely to outperform those in the United States next year, even though U.S. stocks are likely to continue to gain albeit at a more modest pace.
Emerging markets suffered in 2021 “driven by slowdown in China, as well as policy tightening, inflation overhang, EM FX weakness and COVID-19 shocks,” analysts at the bank said in a note on Tuesday. However, “next year, a combination of better EM sentiment (from current lows), stronger earnings growth, and convergence of historical relative valuation, should lead to EM outperformance vs DM.”
In particular, JPMorgan prefers stocks in China, Indonesia, Russia and Brazil, over those in Malaysia and Peru. In developed markets the bank sees Europe as likely to outperform the U.S. and recommends the United Kingdom and Italy over Switzerland.
Sector wise, the bank maintains “a pro-cyclical tilt…with preference for reflation-sensitive sectors.” This includes favoring energy and financials over staples and utilities, consumer services over consumer goods, healthcare over other defensive sectors and small-caps over large-caps.
JPMorgan’s upside targets for 2022 are for the S&P 500 (.SPX) to reach 5050, an approximate 9% increase, while the MSCI Eurozone index (.MIEU00000NEU) will rise to 307, a 17% increase and the FTSE 100 (.FTSE) to reach 8150, a 15% increase.
In emerging markets, the bank expects the MSCI EM index (.MSCIEF) will reach 1500, a 23% increase, while the MSCI China index (.MICN00000PUS) will rise to 116, a 32% increase and the MSCI EMEA (.MIEE00000PUS) will increase to 360, a 34% increase.
THAT WAS QUICK (0832 ET/1332 GMT)
Monday's bounce from Friday's sell-off is proving to be short-lived, with U.S. equity futures pointing to a sharply lower open on renewed concerns about the newly discovered COVID-19 variant, Omicron.
Comments from Moderna (MRNA.O) chief executive Stéphane Bancel to the Finanical Times cast doubt on the effectiveness of vaccines against the new variant, while Regeneron Pharma (REGN.O) said its antibody treatment and other similar drugs could be less effective. read more
Both Moderna and Regeneron shares were lower in premarket, as were travel-related stocks such as airlines and cruise operators while oil prices slumped about 5%. read more
Shortly after the market open 10 a.m. EST (1500 GMT), Fed Chair Jerome Powell and Treasury Secretary Janet Yellen are due to testify before the U.S. Senate Banking Committee, where they are expected to be questioned by lawmakers over high inflation and the potential impact of the new variant. read more
Economic data on tap for the day includes the Chicago PMI and consumer confidence readings for November.
Below is your premarket snapshot:
FOR TUESDAY'S LIVE MARKETS' POSTS PRIOR TO 0830 EST/1330 GMT - CLICK HERE: read more
Register now for FREE unlimited access to Reuters.com
Our Standards: The Thomson Reuters Trust Principles.